Investor Relations
Home Diagnostics, Inc. is a leading pure-play manufacturer and marketer in the rapidly growing $7 billion diabetes testing supplies market. The Company's innovative products are uniquely positioned to capitalize on several distribution models and gain market share with competitive price points. National pharmacy chains, distributors and managed care providers choose to co-brand with Home Diagnostics because its affordable, high-performance products deliver significant savings to these distributors and their customers.
Recent Financial Releases
Feb 3, 2010
Home Diagnostics, Inc. Agrees to Be Acquired by Nipro Corporation; Companies Sign Definitive Agreement
Dec 28, 2009
Home Diagnostics to Present at 28th Annual J.P. Morgan Healthcare Conference
Investor Relations Contact
Nick Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com
| Ticker | HDIX |
| Exchange | NASDAQ | Price | $11.50 |
| Change | - 0.01 |
| Volume | 29,300 |
| Mar 11, 2010 - 12:25 PM ET | |
